This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
== Cause == Growth hormone-producing acidophilic pituitary adenomas are the cause of hypersomatotropism in the vast majority of cats. Both dense and sparse granulated cells has been observed in the adenomas of cats with diabetes mellitus and elevated IGF-1 levels; however, it is not known whether this is because of different variants of the disease or not. It is also not known what percentage of tumours are mixed or plurihormonal tumours. This information has only been reported in studies with a small number of cases. In dogs growth hormone is not just derived from the anterior pituitary gland, it also derives from the mammary gland. Mammary gland production of growth hormone is stimulated by progestogen, this occurs naturally in intact bitches. Synthetic progestogens can cause excessive growth hormone secretion and higher IGF-1 levels which may lead to acromegaly and diabetes mellitus. Progestogens are used to prevent oestrus in bitches and to treat certain hyperplasias. Growth hormone excess can occur in the luteal phase of the oestrous cycle in older bitches. Somatotrophic adenomas have only been described in two dogs. In 1996 a 9-year-old male Doberman Pinscher with difficult to manage diabetes mellitus but no signs of acromegaly was euthanised. Necropsy later revealed an acidophilic adenoma with immunohistochemical staining for growth hormone, adrenocorticotropic hormone, and prolactin.
=== Aspirational === Energy crops: The major combustible component of non-food energy crops is cellulose, with lignin second. Non-food energy crops produce more usable energy than edible energy crops (which have a large starch component), but still compete with food crops for agricultural land and water resources. Typical non-food energy crops include industrial hemp, switchgrass, Miscanthus, Salix (willow), and Populus (poplar) species. A strain of Clostridium bacteria found in zebra dung can convert nearly any form of cellulose into butanol fuel. Another possible application is as Insect repellents.
Although overall yields are comparatively low, Lower Saxony is also an important supplier of crude oil in the European Union. Mineral products still mined today include iron. Radioactive waste is frequently transported in the area to the city of Salzgitter, for the deep geological repository Schacht Konrad and between Schacht Asse II in the Wolfenbüttel district and Lindwedel and Höfer. Manufacturing is another large part of the regional economy. Despite decades of gradual downsizing and restructuring, the carmaker Volkswagen with its five production plants within the state's borders still remains the single biggest private-sector employer, its world headquarters in Wolfsburg. Due to the Volkswagen Law, which has recently been ruled illegal by the European Union's high court, the state of Lower Saxony is still the second-largest shareholder, owning 20.3% of the company. Thanks to the importance of car manufacturing in Lower Saxony, a thriving supply industry is centred around its regional focal points. Other mainstays of the Lower Saxon industrial sector include aviation (the region of Stade is called CFK-Valley), shipbuilding (such as Meyer Werft), biotechnology, and steel. Medicine plays a major role; Hanover and Göttingen have two large University Medical Schools and hospitals, and Otto Bock in Duderstadt is the largest producer of prosthetics and associated componentry in the world. The service sector has gained importance following the demise of manufacturing in the 1970s and 1980s.
As of 2026, there is no cure or effective treatment for CJD. Some of the symptoms, like twitching, can be managed, but otherwise treatment is palliative care. Psychiatric symptoms like anxiety and depression can be treated with sedatives and antidepressants. Myoclonic jerks can be handled with clonazepam or sodium valproate. Opiates can help with pain. Seizures are very uncommon but can nevertheless be treated with antiepileptic drugs. In 2022, results of an early-stage trial of PRN100, a monoclonal antibody against PrP, were reported: the drug appeared safe and reached the brain, but treated patients did not show clearly improved survival compared to historical controls. While not curative, this trial demonstrated the feasibility of immunotherapy for prion disease. In 2025, preclinical research demonstrated that oral, low-dose treatment with the antiretroviral medication efavirenz extended survival and slowed disease progression in a humanized mouse model of sporadic CJD (sCJD). The drug acts as an allosteric activator of the brain-specific cholesterol-metabolizing enzyme CYP46A1. This mechanism promotes brain cholesterol turnover, reduces the neurotoxic accumulation of pathological prion proteins (PrPSc), and alleviates metabolic lipid alterations in the brain.
Sources: en.wikipedia.org
== Example case: bacterial plasmid subcloning == In this example, a gene from mammalian gene library will be subcloned into a bacterial plasmid (destination platform). The bacterial plasmid is a piece of circular DNA which contains regulatory elements allowing for the bacteria to produce a gene product (gene expression) if it is placed in the correct place in the plasmid. The production site is flanked by two restriction enzyme cutting sites "A" and "B" with incompatible sticky ends. The mammalian DNA does not come with these restriction sites, so they are built in by overlap extension PCR. The primers are designed to put the restriction sites carefully, so that the coding of the protein is in-frame, and a minimum of extra amino acids is implanted on either side of the protein. Both the PCR product containing the mammalian gene with the new restriction sites and the destination plasmid are subjected to restriction digestion, and the digest products are purified by gel electrophoresis. The digest products, now containing compatible sticky ends with each other (but incompatible sticky ends with themselves) are subjected to ligation, creating a new plasmid which contains the background elements of the original plasmid with a different insert. The plasmid is transformed into bacteria and the identity of the insert is confirmed by DNA sequencing.
==== Carnivoran research ==== Evidence of impact of competition on diversification of North American and Eurasian carnivorans throughout the last 45 million years is presented by Porto & Quental (2026). A study on the mandibles of extant and extinct carnivorans, providing evidence of overall decoupling of evolution of mandible shape and function, but also possible evidence of modular dynamics in the evolution of mandible, with differences in the pace and correlation of evolution of different anatomical regions, is published by Sansalone et al. (2026). Bartolini-Lucenti et al. (2026) document new occurrences of carnivorans in the Pliocene strata from the Jradzor locality (Armenia), including Baranogale helbingi, Chasmaporthetes lunensis, Pliocrocuta perrieri and cf. Lynx sp., expanding known geographic and temporal ranges of the studied carnivorans. Orcutt et al. (2026) report the discovery of new carnivoran fossil material from the John Day Formation (Oregon, United States), including the first definitive records of Osbornodon sp. and Otarocyon sp. from the studied formation, as well as a possible fossil material of a large amphicyonine. Espinasa et al. (2026) study the composition of the Rancholabrean carnivoran assemblage from the Calera cave system (San Luis Potosí, Mexico), including a growth sequence of Smilodon fatalis. Díaz de León-Muñoz, Siliceo & Ferreira (2026) study the feeding behavior of Magericyon anceps, reporting evidence of resistance of its mandible to loads during hunting, but also evidence of an unexpectedly weak bite.
=== Wallets === A number of technologies known as wallets exist that store the key value pair of private and public key known as wallets. A wallet hosts the details of the key pair making cryptocurrency transactions possible. Multiple methods exist for storing keys or seeds in a wallet. A brainwallet or brain wallet is a type of wallet in which one memorizes a passcode (a private key or seed phrase). Brainwallets may be attractive due to plausible deniability or protection against governmental seizure, but are vulnerable to password guessing (especially large-scale offline guessing). Several hundred brainwallets exist on the Bitcoin blockchain, but most of them have been drained, sometimes repeatedly.
Sources: en.wikipedia.org
When cells divide, their full genome is copied and each daughter cell inherits one copy. This process, called mitosis, is the simplest form of reproduction and is the basis for asexual reproduction. Asexual reproduction can also occur in multicellular organisms, producing offspring that inherit their genome from a single parent. Offspring that are genetically identical to their parents are called clones. Eukaryotic organisms often use sexual reproduction to generate offspring that contain a mixture of genetic material inherited from two different parents. The process of sexual reproduction alternates between forms that contain single copies of the genome (haploid) and double copies (diploid). Haploid cells fuse and combine genetic material to create a diploid cell with paired chromosomes. Diploid organisms form haploids by dividing, without replicating their DNA, to create daughter cells that randomly inherit one of each pair of chromosomes. Most animals and many plants are diploid for most of their lifespan, with the haploid form reduced to single cell gametes such as sperm or eggs. Although they do not use the haploid/diploid method of sexual reproduction, bacteria have many methods of acquiring new genetic information. Some bacteria can undergo conjugation, transferring a small circular piece of DNA to another bacterium. Bacteria can also take up raw DNA fragments found in the environment and integrate them into their genomes, a phenomenon known as transformation.
== Selected-reaction monitoring chromatogram (SRM, MRM) == The selected-reaction monitoring (SRM) experiment is very similar to the SIM experiment except that tandem mass spectrometry is used and a specific product ion of a specific parent ion is detected. The mass of the parent analyte is first selected while other ions are filtered away. The parent analyte ion is then fragmented in the gas phase and a specific fragment ion is monitored. This experiment has very high specificity because the SRM chromatogram represents only ions of a particular mass that fragment in a manner that produce a very specific product mass. This type of experiment can only be performed using tandem mass spectrometry. The technology progress in the MS/MS area lead to the development of MRM, Multiple Reaction Monitoring, which allows simultaneous detection of several coeluting analytes with different parent and/or product ions.
== Medical uses == Levothyroxine is typically used to treat hypothyroidism, and is the treatment of choice for people with hypothyroidism who often require lifelong thyroid hormone therapy. It may also be used to treat goiter via its ability to lower thyroid-stimulating hormone (TSH), which is considered goiter-inducing. Levothyroxine is also used as interventional therapy in people with nodular thyroid disease or thyroid cancer to suppress TSH secretion. A subset of people with hypothyroidism treated with an appropriate dose of levothyroxine will describe continuing symptoms despite TSH levels in the normal range. In these people, further laboratory and clinical evaluation is warranted, as they may have another cause for their symptoms. Furthermore, reviewing their medications and dietary supplements is important, as several medications can affect thyroid hormone levels. Levothyroxine is also used to treat subclinical hypothyroidism, which is defined by an elevated TSH level and a normal-range free T4 level without symptoms. Such people may be asymptomatic and whether they should be treated is controversial. One benefit of treating this population with levothyroxine therapy is preventing the development of hypothyroidism. As such, treatment should be taken into account for patients with initial TSH levels above 10 mIU/L, people with elevated thyroid peroxidase antibody titers, people with symptoms of hypothyroidism and TSH levels of 5–10 mIU/L, and women who are pregnant or want to become pregnant. Oral dosing for patients with subclinical hypothyroidism is 1 μg/kg/day.
In May 2012, the ONDCP published "Principles of Modern Drug Policy", broadly focusing on public health, human rights, and criminal justice reform, while targeting drug traffickers. According to ONDCP director Kerlikowske, drug legalization is not the "silver bullet" solution to drug control, and success is not measured by the number of arrests made or prisons built. That month, a joint statement, "For a humane and balanced drug policy", was signed by Italy, Russia, Sweden, the United Kingdom and the US, promoting a combination of "enforcement to restrict the supply of drugs, with efforts to reduce demand and build recovery." Meanwhile, at the state level, 2012 saw Colorado and Washington become the first two states to legalize the recreational use of cannabis with the passage of Amendment 64 and Initiative 502 respectively. A 2013 ACLU report declared the anti-marijuana crusade a "war on people of color". The report found that "African Americans [were] 3.73 times more likely than whites to be apprehended despite nearly identical usage rates, and marijuana violations accounting for more than half of drug arrests nationwide during the previous decade". Under Obama's policies, nonwhite drug offenders received less excessive criminal sanctions, but by examining criminals as strictly violent or nonviolent, mass incarceration persisted.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.